The stock price of LaserOptek, a specialized company in laser devices for skin beauty and disease treatment, is on the rise. The news that the laser device ‘Piccolo Premium’ has received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and is entering full-scale sales appears to be influencing the stock price.
Among investors who have observed the growth of Classys, a leading domestic beauty and medical device company, movements to find the 'second Classys' are accelerating. Classys, which was listed on the KOSDAQ market in 2017, had its stock price hovering around 2,000 KRW. Its sales grew more than sixfold from 46.1 billion KRW in 2018 to 243 billion KRW last year. The stock price surpassed 60,000 KRW, and its market capitalization is approaching 4 trillion KRW.
As of 10:17 AM on the 27th, LaserOptek is trading at 8,990 KRW, up 22.98% from the previous day. Its market capitalization has exceeded 100 billion KRW.
The PMDA is a registration and management agency for pharmaceuticals and medical devices under Japan’s Ministry of Health, Labour and Welfare, known for its stringent approval procedures and lengthy processing times.
In 2021, LaserOptek received PMDA approval for the PALLAS laser, becoming the first domestic skin beauty laser company to obtain approval for a laser device treating intractable skin diseases, thereby already gaining recognition for its technology in Japan.
Piccolo Premium has now obtained approvals from Korea’s Ministry of Food and Drug Safety, the U.S. FDA, Europe’s CE, Taiwan’s TFDA, and most recently Japan’s PMDA, making it a laser device that has secured approvals in all major advanced global markets.
Based on Nd:YAG technology, Picosecond skin beauty laser, Piccolo Premium is one of LaserOptek’s core devices along with Helios785 and Pallas Premium. It is praised for realizing a true picosecond laser through stable pulse width and output.
Picosecond contouring is a protocol specialized in anti-aging and rejuvenation that improves jawline, cheek tightening, wrinkles around the eyes and mouth, whitening, tone improvement, and overall facial contours using Piccolo Premium. This procedure was proposed by Dr. Philip Woschler, a master in the field of skin beauty procedures in the U.S. Since then, successful clinical cases in the U.S. and Europe have drawn industry attention.
LaserOptek CEO Changjin Lee said, "With Piccolo Premium receiving approval in Japan following Piccolo and Pallas, we have built a solid product portfolio," adding, "We currently have a dedicated local manager in Japan focusing on sales and marketing."
Founded in 2000, LaserOptek is a laser-based medical device specialist company that exports products under its own brand to about 50 countries and is used in dermatology clinics and hospitals worldwide. It achieved sales of 34.4 billion KRW in 2023 and was listed on KOSDAQ in February this year. Through differentiated technology, a diverse product portfolio, and strengthened overseas sales, it aims to achieve sales of approximately 80 billion KRW by 2027.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
